Protection without Capture: Product Approval by a Politically Responsive, Learning Regulator
By D. Carpenter. American Political Science Review, 2004
204 citations recorded by the source corpus.
Subfields: Economics and Econometrics, Management of Technology and Innovation, Strategy and Management
View Paper: https://www.semanticscholar.org/paper/cbdc81711182453b076090a2532b7eddbeb978d6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Economics and Econometrics
- Steven Callander
- Wouter P. C. Boon
- J. Edler
- D. Carpenter
- Michael M. Ting
- C. Volden
- Barry R. Weingast
- Elvira Uyarra
In Management of Technology and Innovation
In Strategy and Management
Citations in the corpus
- A Formal Model of Learning and Policy Diffusion (2008, background): “This characterization of the valence benefit (or cost) as only revealed and experienced with some probability embodies a number of simplifying assumptions.7 The draws of ωt1j are independent across both time and states.”
- Searching for Good Policies (2011, background): “…changes in outcome may not be so regular or predictable, and it is reasonable to 2 The Brownian motion has appeared in political science in work by Carpenter (2002, 2004), although he uses the process in the classic manner as evolving through time. suppose that sometimes the change in outcome is…”
- Lords of the Harvest: Third-Party Influence and Regulatory Approval of Genetically Modified Organisms (2013, unknown): “Given that larger firms are likely to command both greater resources and greater power to affect regulatory decisions (Carpenter, 2004; Stigler, 1971), we controlled for firm size, defined as number of employees (Hiatt & Sine, 2013).”
- Demand, challenges, and innovation. Making sense of new trends in innovation policy (2018, background): “This becomes, for instance, clear in the case of interactions between pharmaceutical companies and regulatory agencies about the safety and efficacy of medicinal products (Carpenter 2004).”